Alerts will be sent to your verified email
Verify EmailSUVEN
Suven Life Sciences
|
Kilitch Drugs(India)
|
Gufic Biosciences
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
490.0 % | n/a | 1.06 % |
Financials
|
|||
5 yr Average ROE
|
-60.19 % | 3.79 % | 26.14 % |
5yr average Equity Multiplier
|
1.83 | 1.38 | 2.82 |
5yr Average Asset Turnover Ratio
|
0.18 | 0.5 | 1.1 |
5yr Avg Net Profit Margin
|
-620.16 % | 5.1 % | 9.03 % |
Price to Book
|
8.57 | 3.11 | 6.83 |
P/E
|
0.0 | 37.58 | 42.23 |
5yr Avg Cash Conversion Cycle
|
28.38 Days | -70.11 Days | -18.02 Days |
Inventory Days
|
1.27 Days | 19.8 Days | 77.22 Days |
Days Receivable
|
28.38 Days | 125.11 Days | 81.36 Days |
Days Payable
|
41.02 Days | 169.05 Days | 175.58 Days |
5yr Average Interest Coverage Ratio
|
-134.43 | 7.08 | 10.3 |
5yr Avg ROCE
|
-58.7 % | 6.74 % | 33.27 % |
5yr Avg Operating Profit Margin
|
-623.89 % | 12.08 % | 17.37 % |
5 yr average Debt to Equity
|
0.01 | 0.12 | 0.73 |
5yr CAGR Net Profit
|
37.69 % | 22.23 % | 29.43 % |
5yr Average Return on Assets
|
-31.45 % | 2.69 % | 10.17 % |
Shareholdings
|
|||
Promoter Holding
|
69.57 % | 69.23 % | 72.51 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
9.57 % | 0.6 % | 6.76 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.84 % | 0.0 | -6.16 % |
Suven Life Sciences
|
Kilitch Drugs(India)
|
Gufic Biosciences
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|